Literature DB >> 17955173

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.

Peer Tfelt-Hansen1.   

Abstract

The clinical efficacy in migraine was compared for oral and subcutaneous sumatriptan and naratriptan. Doses of the two administration forms were chosen as resulting in comparable blood concentrations. Subcutaneous administrations of the drugs were superior for efficacy than the oral forms. This most likely due to a quicker rise in blood concentrations after subcutaneous injections.. In designing new therapies for migraine one should aim at a quick absorption of the drug, which will probably result in an increased efficacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17955173      PMCID: PMC3476154          DOI: 10.1007/s10194-007-0411-x

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  21 in total

1.  Treatment of acute cluster headache with sumatriptan.

Authors: 
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

Review 2.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.

Authors:  P Tfelt-Hansen; P De Vries; P R Saxena
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study.

Authors: 
Journal:  Eur J Neurol       Date:  1998-09       Impact factor: 6.089

4.  Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.

Authors:  H Havanka; C Dahlöf; P H Pop; H C Diener; P Winter; H Whitehouse; H Hassani
Journal:  Clin Ther       Date:  2000-08       Impact factor: 3.393

5.  Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.

Authors:  N T Mathew; M Asgharnejad; M Peykamian; A Laurenza
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

6.  Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group.

Authors:  N T Mathew; J Dexter; J Couch; W Flamenbaum; J Goldstein; A Rapoport; F Sheftell; J Saper; S Silberstein; S Solomon
Journal:  Arch Neurol       Date:  1992-12

7.  Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group.

Authors:  W H Visser; M D Ferrari; E M Bayliss; S Ludlow; A J Pilgrim
Journal:  Cephalalgia       Date:  1992-10       Impact factor: 6.292

Review 8.  Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials.

Authors:  P Tfelt-Hansen
Journal:  Cephalalgia       Date:  1993-08       Impact factor: 6.292

9.  Single dose pharmacokinetics of sumatriptan in healthy volunteers.

Authors:  L F Lacey; E K Hussey; P A Fowler
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Maximum effect of triptans in migraine? A comment.

Authors:  P Tfelt-Hansen
Journal:  Cephalalgia       Date:  2008-07       Impact factor: 6.292

View more
  11 in total

Review 1.  Taking the negative view of current migraine treatments: the unmet needs.

Authors:  Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

2.  Low efficacy of transdermal sumatriptan in migraine.

Authors:  Peer Tfelt-Hansen
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

Review 3.  Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.

Authors:  Andrea Stephanie Link; Anikó Kuris; Lars Edvinsson
Journal:  J Headache Pain       Date:  2008-01-23       Impact factor: 7.277

Review 4.  Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.

Authors:  Peer Tfelt-Hansen; Karl Messlinger
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

5.  Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.

Authors:  Anna Ferrari; Diego Pinetti; Alfio Bertolini; Ciro Coccia; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2008-01-08       Impact factor: 2.953

Review 6.  Migraine pain: reflections against vasodilatation.

Authors:  Alessandro Panconesi; Maria Letizia Bartolozzi; Leonello Guidi
Journal:  J Headache Pain       Date:  2009-06-05       Impact factor: 7.277

Review 7.  Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.

Authors:  Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2011-02-25       Impact factor: 7.277

Review 8.  Why pharmacokinetic differences among oral triptans have little clinical importance: a comment.

Authors:  Anna Ferrari; Ilaria Tiraferri; Laura Neri; Emilio Sternieri
Journal:  J Headache Pain       Date:  2010-09-29       Impact factor: 7.277

9.  Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.

Authors:  Stewart J Tepper; Raghavendra Vasudeva; John H Krege; Suchitrita S Rathmann; Erin Doty; Bert B Vargas; Delphine Magis; Mika Komori
Journal:  Headache       Date:  2020-07-07       Impact factor: 5.887

10.  Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment.

Authors:  Peer C Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-09-25       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.